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One of the main research areas in biology from the mid-1980s through the 1990s
was the elucidation of signaling pathways governing cell responses. These studies
brought, among other molecules, the small GTPase Rho to the epicenter. Rho sig-
naling research has since expanded to all areas of biology and medicine. Here, we
describe how Rho emerged as a key molecule governing cell morphogenesis and
movement, how it was linked to actin reorganization, and how the study of Rho sig-
naling has expanded from cultured cells to whole biological systems. We then give
an overview of the current research status of Rho signaling in development, brain,
cardiovascular system, immunity and cancer, and discuss the future directions of
Rho signaling research, with emphasis on one Rho effector, ROCK*.
*The Rho GTPase family. Rho family GTPases have now expanded to
contain 20 members. Amino acid sequences of 20 Rho GTPases found in
human were aligned and the phylogenetic tree was generated by ClustalW2
software (EMBL-EBI) based on NJ algorithm. The subfamilies of the Rho
GTPases are highlighted by the circle and labeled on the right side. Rho
cited in this review refers to the original members of Rho subfamily,
RhoA, RhoB and RhoC, that are C3 substrates, and, unless specified, not
to other members of the Rho subfamily such as Rac, Cdc42, and Rnd.
Keywords: actin; actomyosin; C3 exoenzyme; myosin; Rho; ROCK; SRF;
Y-27632
Abbreviations
ECM, extracellular matrix; LPA, lysophosphatidic acid; MLC, myosin light chain; MRTF, myocardin-related transcription factor; PBMCs,
peripheral blood mononuclear cells; ROCK, Rho-associated coiled-coil containing kinase; SRF, serum response factor.
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Discovery of Rho and botulinum C3
exoenzyme; the dawn of Rho research
In the mid-1980s, there was a transition in signal
transduction research. While prototypes of transmem-
brane signaling such as heterotrimeric G proteins and
G-protein coupled receptors, receptor tyrosine kinases,
channels and transporters, had been identified and
cloned, little was known on how the signals trans-
mitted within the cell evoke cell responses such as
proliferation, exocytosis and adhesion. Although
involvement of GTP in some of these responses was
reported, molecules bearing such GTP-dependent func-
tions were far from identification. An exception was
Ras, which had been identified as retrovirus-coded
oncogenes encoding a 21 kDa GTP-binding protein,
but its action mechanism also remained an enigma. In
this situation, Madaule and Axel serendipitously iden-
tified the first Ras homolog in Aplysia, and named it
Rho [1]. They further detected Rho genes in human
and rat, and suggested that those of human possibly
consist of three members, which were later named
RhoA, B, and C. However, without any biological
findings, little attention was paid to it.
One approach to discover mechanisms and princi-
ples working in biological processes is to find out
pharmacological tools interfering with such processes
by specifically targeting the molecules involved. Given
the demonstrated usefulness of cholera toxin and per-
tussis toxin as probes of heterotrimeric G-proteins, Gs
and Gi/Go, respectively [2] and the fact that most of
the bacterial toxin ADP-ribosyltransferases target
GTP-binding proteins [2], we sought a novel bacterial
ADP-ribosyltransferase activity, and identified in
preparations of botulinum C1 and D toxin an enzyme
that ADP-ribosylates a 22 kDa GTP-binding protein
in mammalian cells. We reported these findings in the
Journal of Biological Chemistry on February 5, 1987
[3]. To our surprise, the same enzyme activity was
reported in the February 9, 1987, issue of FEBS Let-
ters by Aktories and collaborators [4]. They later fur-
ther reported that this ADP-ribosyltransferase is
distinct from botulinum neurotoxins and named it C3
exoenzyme [5]. Almost 1 year later, Rubin et al. con-
firmed these findings and additionally reported that
the C3 treatment induced morphological changes in
cultured cells, typically the rounding up of fibroblasts
and epithelial cells and the neurite extension of neu-
ronal cells [6], which we also noted separately [7,8].
However, the identity of the target GTP-binding pro-
tein was not elucidated until we purified and identified
it as Rho [9–11]. Our studies thus merged researches
on Rho and C3. Chardin et al. then reported that
actin microfilaments were lost in C3-treated round-up
Vero cells [12]. The next question was therefore how
the morphological phenotype of C3-treated cells is
related to the function of Rho and how Rho is
involved in actin microfilament assembly. Because little
was known about the difference between the Rho iso-
forms, most of the early studies in the field were
focused on RhoA.
Rho as a molecular switch for actin
cytoskeleton reorganization
According to the analogy to Ras, it was thought that
Rho is activated from the GDP-bound form to the
GTP-bound form to exert its actions. So, the above
question could be addressed by comparing the C3 phe-
notype with that induced by active Rho. This was
exactly where Alan Hall and collaborators entered the
field, using their expertise in Ras biochemistry and
microinjection technique. They microinjected Val14-
RhoA, a presumably active RhoA mutant with
reduced GTPase activity, and found extensive actin fil-
ament assembly in the contracted body of microin-
jected cells [13]. Although this Val14-RhoA phenotype
appeared opposite to the above phenotype of C3-trea-
ted cells, it was not clear at this time what kind of cell
structures and what kind of cell response they repre-
sent. Ridley and Hall addressed these points [14]. They
showed that the actin filament structure induced by
active RhoA in fibroblasts represents actin stress fibers
linked to focal adhesions, that these structures are
induced by the addition of serum to the cells, and that
this induction was inhibited by microinjection of C3 or
ADP-ribosylated Rho, thus making clear that Rho
works as a molecular switch in stimulus-induced stress
fiber formation. By this time, homology cloning and
protein purification identified a variety of Ras-related
GTP-binding proteins in mammals and yeast. Dids-
bury et al. [15] isolated two cDNAs highly homolo-
gous to Rho from HL-60 kibrary, and erroneously
named Rac (Ras-related C3 substrate) 1 and 2. Ridley
and Hall therefore extended their study to examine the
function of Rac1, and reported that Rac1 induces a
different actin filament structure, membrane ruffles, in
response to PDGF [16]. Their works thus established
the paradigm that Rho GTPases function as molecular
switches for actin reorganization.
Focal adhesion induced by Rho is the multi-protein
complex of integrin and associated proteins, which is
clustered by the force of actomyosin bundles ligated
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to this complex, and serves as adhesion to extracellu-
lar matrix (ECM). Therefore, Rho-induced focal
adhesion formation facilitates cell adhesion to ECM
by increasing the integrin avidity. We confirmed
RhoA action with platelet aggregation as an example,
which is mediated by binding of platelet integrin
GPIIb/IIIa to soluble ECM ligands such as fibrino-
gen [17].
Other notable examples of Rho-regulated cell pro-
cesses were neurite retraction and cytokinesis. In the
above work on stress fibers, Ridley and Hall identified
a major RhoA activating factor in serum as lysophos-
phatidic acid (LPA). The biological activity of this
lipid was found by Wouter Moolenaar, who also
found that the addition of LPA induces neurite retrac-
tion in neuroblastoma cells. Hearing his talk at our
Department seminar, we noticed that this LPA pheno-
type was opposite to neurite extension by the C3 treat-
ment. We therefore collaborated and found that RhoA
mediates neurite retraction induced by LPA [18]. We
also collaborated with Issei Mabuchi on the role of
Rho in cytokinesis, and found that the C3 treatment
aborted cytokinesis by abolishing the contractile ring,
indicating that Rho links nuclear division to cytoplas-
mic division through induction of the contractile ring
[19]. Kishi et al. analyzed the division of Xenopus
embryos and reached the same conclusion [20].
Intriguingly, Treisman and collaborators found that
LPA also activates the transcription factor “serum
response factor (SRF)” and this activation also
requires functional RhoA [21]. Their later studies
showed that SRF activity is regulated by SRF tran-
scriptional coactivator myocardin-related transcription
factor (MAL/MRTF) and that the interaction between
SRF and MAL/MRTF is inhibited by the binding of
MAL/MRTF to G-actin [22]. Upon RhoA activation,
G-actin is incorporated into F-actin and MAL/MRTF
is subsequently released from G-actin. This facilitates
the formation of SRF-MAL/MRTF complexes and
thus the activation of SRF-dependent transcription of
genes that are involved in a variety of cellular pro-
cesses such as cell migration, cell proliferation and cell
differentiation [23].
Search and identification of Rho
effectors; elucidation of molecular
mechanisms of Rho actions
Both stress fibers and the contractile ring are com-
posed of actomyosin bundles and neurite retraction is
caused by their contraction. These findings led us to
hypothesize that the action of Rho is to make actin fil-
aments from actin monomers and then cross-link them
by activating myosin for contraction. So, the next issue
of Rho research was to find out molecules and mecha-
nisms underlying these steps, which are presumably
carried out by effector molecules downstream of Rho.
Since the GTP-bound and not GDP-bound Rho exerts
its actions, effector molecules were presumed to bind
selectively to the GTP-bound Rho. Isolation of small
GTPase effectors by such selective binding was her-
alded by Louis Lim and collaborators, who isolated
p65PAK (PAK1) as a Cdc42/Rac effector in 1994 [24].
Using selective binding to the GTP-bound Rho in
ligand overlay assay or yeast two hybrid systems, we
isolated several Rho effectors [25–29]. One of them is
Rho-associated coiled-coil containing kinase (ROCK),
which consists of two isoforms, ROCK-I (ROCK1)
and ROCK-II (ROCK2) [26,30]. The same enzymes
were isolated and called ROK and Rho-kinase by
Louis Lim’s group [31] and Kozo Kaibuchi’s group
[32], which correspond to ROCK-I and ROCK-II,
respectively. Another effector we isolated was a mam-
malian homolog of Diaphanous (mDia) [29], which
belongs to the formin family and consists of three iso-
forms [33]. Expression of active ROCK produced acto-
myosin bundles reminiscent of stress fibers and
extensive formation of focal adhesions in HeLa cells
[34,35] presumably through activation of myosin (see
below), and expression of active mDia increased the
density of actin filaments [29], suggesting that it
induces actin polymerization. The actin nucleation/
polymerization activity of the formin family was later
shown in yeast formin, Bni1p [36] and then mDia [37].
Co-expression of ROCK and mDia produced beauti-
fully aligned stress fibers in HeLa cells, thus reproduc-
ing the action of Rho on stress fiber formation [38].
Thus, mDia and ROCK are thought as main effectors
in Rho-induced actin reorganization (Fig. 1).
Discovery of Y-27632, a specific
ROCK inhibitor; a pivotal point from
cell biology to physiology
Smooth muscle contraction is triggered by myosin
light chain (MLC) phosphorylation. The involvement
and mechanism of ROCK in myosin activation was
revealed both biochemically and pharmacologically by
the analysis of the so called “calcium-sensitization
pathway” of smooth muscle contraction. This pathway
augments contraction at a fixed intracellular calcium
ion concentration [Ca2+]I, and was previously demon-
strated to involve GTP, RhoA and myosin phos-
phatase [39,40]. Kaibuchi’s group showed that Rho
kinase/ROCK phosphorylates myosin-binding subunit
of myosin phosphatase, thus inactivating the
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phosphatase and consequently raising MLC phospho-
rylation and contraction [41]. The involvement of
ROCK in this process was also confirmed pharmaco-
logically using Y-27632. Y-27632 was developed as a
compound that inhibits the calcium-sensitization path-
way of smooth muscle contraction, and the photo-affi-
nity cross-linking and the assay on recombinant
ROCK identified it as a selective ROCK inhibitor [42].
This inhibitor not only inhibited the calcium-sensitiza-
tion of smooth muscle selectively but also abolished
RhoA-induced formation of stress fibers and focal
adhesions. This compound further inhibits the RhoA-
mediated neurite retraction in neuroblastoma cells and
analysis of this effect revealed the RhoA-mediated
inhibition of actin depolymerization through the
ROCK-LIM kinase-cofilin pathway [43]. Thus, identifi-
cation of Rho effectors and a ROCK-specific inhibitor
facilitated elucidation of molecular mechanisms of
Rho-mediated cellular responses. The impact of the
discovery of Y-27632, however, was not limited to
analysis of cultured cells but also on intact animals, in
which Y-27632 is used to examine possible involve-
ment of Rho-ROCK signaling in various physiological
and pathophysiological processes as described below.
Thus, the discovery of Y-27632 made a pivotal point
in Rho research.
Fig. 1. (A) Simplified scheme depicting the actions of mDia and ROCK in Rho-mediated actin remodeling. Upon the activation by Rho, mDia
promotes actin nucleation and polymerization to form actin filaments and ROCK activates myosin to bundles actin filaments. The upper right
box shows the FH1FH2 of mDia1-catalyzed actin polymerization in vitro. Red arrowheads indicate the mDia1-free barbed end of F-actin
growing at slow rate, and blue arrowheads indicate the barbed end undergoing mDia1 (FH1FH2)-dependent fast growth. Times are indicated
in seconds. Scale bar, 5 lm. Modified from Yamashiro S, et al. MBoC 25, 1010–1024 (2014). The lower right box shows F-actin staining of
HeLa cells overexpressing vector control or active ROCK-I. Note that F-actin bundles are extensively induced in active ROCK-I
overexpressed cells. Modified from Ishizaki T, et al. FEBS Lett. 404, 118–124 (1997). (B) Crystal structures of Y-27632-bound (left) and
fasudil-bound (right) kinase domain of ROCK-I. Modified from Jacobs M, et al. JBC 281, 260–268 (2006).
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Rho signaling research in current
status
With the spread of the knowledge on Rho signaling in
various cell processes and the advent of various dis-
secting tools, that is, drugs, expression constructs,
RNAi and transgenic, and knockout animals, Rho sig-
naling research has spread widely to all areas of biol-
ogy. Here, we select several fields and overview their
current status.
Development and regeneration
Rho signaling functions critically in several develop-
mental processes (Fig. 2). Its typical mode of action
here is to form actomyosin bundles traversed intercel-
lularly by connecting neighboring epithelial cells
through cell-cell adhesion and contract them for tissue
morphogenesis and maintenance. Both ROCK and
mDia are involved. For example, mice-deficient in
either ROCK-I or ROCK-II fail in closure of the eye-
lid and the ventral body wall and are born with the
‘eyes open at birth’ and omphalocele phenotype. In
these mice, actin cables that encircle the eye in the
epithelial cells of the eyelid as well as those encircling
the umbilical ring are disorganized [44–46]. Although
each of ROCK-I and ROCK-II exhibits distinct roles
in many circumstances described below, they appar-
ently act functionally redundant in these closure pro-
cesses. In mDia1/3 double KO mice, apical actin belts
in neuroepithelial cells were attenuated and their apical
adherens junctions were impaired, resulting in the loss
of apical-basal polarity of neuroepithelial cells and
periventricular hyperplasia [47]. When such apical
actomyosin cables contract, it causes apical constric-
tion of epithelial cells and, making cuboidal cells to
trapezoid, bending tissues and forming three-dimen-
sional structures such as tube and invagination. This is
seen in gastrulation and neurulation, where Rho,
ROCK and mDia function [48]. In chick neural tube
formation, cadherin, Celsr1, recruits PDZ-RhoGEF at
the mediolateral adherens junctions to upregulate
Rho-ROCK signaling and cause actomyosin contrac-
tion apically in a planar-polarized manner [49,50]. A
similar role of Rho-ROCK signaling in planar cell
polarity was reported in Drosophila germ band exten-
sion [51]. Furthermore, ROCK functions also in mak-
ing convex invagination in optic-cup-like structure
formation from ES cells in culture [52]. In addition,
the polarized localization of ROCK causes biased
actomyosin activity in a single cell, and this mecha-
nism operates crucially in asymmetric cell division of
Drosophila neural stem cells [53].
YAP and TAZ are effectors of the Hippo signaling
involved in control of organ size, stem cell renewal,
regeneration and cancer [54]. They are also involved in
mechanotransduction, and translocate to the nucleus
on sensing of ECM stiffness and cell spreading in
Rho- and actomyosin tension-dependent manners [55].
Requirement of Rho signaling is also observed in acti-
vation of YAP/TAZ by Wnt signaling, in which Wnt
activates Rho through FZD-ROR-Ga12/13 pathway
and inhibits Lats1/2 [56]. This Rho-mediated activa-
tion of YAP/TAZ is required for long-term survival
and expansion of human ES cells cultured en bloc [57].
Interestingly and paradoxically, dissociated human ES
cells exhibit Rho-ROCK-mediated hyperactivation of
myosin and the resultant contraction induces their
death, which can be rescued by Y-27632 [58–60].
Brain morphogenesis and function
Rho signaling is involved in brain morphogenesis and
functions including axonogenesis, neuronal migration
and synaptic plasticity. Neurite retraction in cultured
neuron is mediated by ROCK [61,62] and ROCK2
KO mice exhibited enhanced axonogenesis after spinal
cord injury and recovered faster than the control mice
[63]. The Rho-ROCK signaling is now recognized as
the final common pathway to limit axonogenesis in
CNS trauma and the potential of ROCK inhibitor in
axonal regeneration is being examined [64]. Notably,
this Rho-ROCK action operates in not only such
pathophysiological process but also neuronal develop-
ment. Kaibuchi’s group recently showed that the grow-
ing axon transmits long-range Ca2+ waves to other
neurites, activates RhoA-ROCK pathway there and
suppresses their axonogenesis to allow the formation
of a single axon in neurons [65]. Rho signaling also
works in neuronal migration; mice deficient in mDia1
and 3 in combination exhibit deficit in tangential
migration of interneuron precursors from subventricu-
lar zone to the olfactory bulb [66]. Moreover, Rho sig-
naling plays critical roles in synaptic plasticity. The
dendritic spine is the site of memory. Rac and Rho
work antagonistically in shaping dendritic spines,
growth and shrinkage, respectively, and ROCK medi-
ates the latter Rho action [67]. By this action, ROCK
apparently is involved in some types of mental retarda-
tion, where a Rho GTPase activating protein named
oligophrenin-1 is mutated; down-regulation of oligo-
phrenin-1 results in spine shrinkage, which is rescued
by ROCK inhibitor [68]. In addition to these postsy-
naptic actions, ROCK functions in synaptic vesicle
retrieval in the presynaptic terminal to contribute to
the homeostatic balance of vesicle exocytosis and
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endocytosis at synapse [69]. Furthermore, Rho signal-
ing is involved in plasticity of the presynaptic terminal.
Deguchi et al. [70] found that social isolation of mice
induces inactivation of Nucleus accumbens neurons,
which then leads to mDia and ROCK-dependent con-
traction of their terminals in the Ventral tegmental
area and reduces synaptic transmission there, which
causes enhanced anxiety behavior in these animals.
These actions of Rho-ROCK signaling could be
involved in synaptic plasticity in the lateral amygdala
associated with fear conditioning as well as that in pre-
limbic prefrontal cortex associated with goal-directed
decision making, both of which is sensitive to ROCK
inhibition [71,72].
Cardiovascular system
Since Y-27632 was discovered through screening for
compounds that inhibit calcium sensitization of arte-
rial contraction and shown to lower blood pressure in
various rat models of hypertension [42], much interest
has arisen naturally in the role of Rho-ROCK signal-
ing in the cardiovascular system. Such interest was
boosted further by the finding that fasudil, a drug
Fig. 2. Examples of the ROCK actions in development. The left box shows the impaired eyelid closure phenotype of ROCK-I/ embryos.
Scanning electron micrographs of the eyes of the WT and ROCK-I/ embryos are shown on the top and whole-mount F-actin staining of
the eyelids of WT and ROCK-I/ embryos are shown on the bottom. Note that F-actin bundles encircling the eye (arrowheads) are impaired
in ROCK-I/ embryos. Modified from Shimizu Y, et al. JCB 168, 941–953 (2005). The right box shows the role of ROCK in neural tube
closure. H&E staining of mouse embryo neural tube is shown on the top left (H. Kamijo, T. Ishizaki, D. Thumkeo, S. Narumiya, et al.,
unpublished results). The upper three panels show immunofluorescence micrographs of chick embryo neural tube during neural tube
closure. Modified from Nishimura T, et al. Development 141, 1987–1998 (2008) and Nishimura T, et al. Cell 149, 1084–1097 (2012). Note
concentration of ROCK-I and pMLC on the apical surface as marked by ZO-1 staining. The lower panels show stereomicroscope
micrographs of 9.5 dpc mouse embryo neural tube (H. Kamijo, T. Ishizaki, D. Thumkeo, S. Narumiya, et al., unpublished results). Note
impaired neural tube closure of ROCK-I+/; ROCK-II/ mouse embryo (white arrow). A model proposes the role of ROCK-mediated
actomyosin on the apical surface of neuroepithelium during neural tube closure is shown on the bottom right.
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approved in Japan for treatment of vasospasm after
subarachnoid hemorrhage, is also a ROCK inhibitor
[73], which has stimulated studies not only in animals
but also in humans. For example, fasudil is effective in
decreasing the frequency of attacks in stable angina
patients [74] and attenuating coronary artery vasos-
pasm in patients with vasospastic angina, the effect
reproduced in the porcine model with enhanced myo-
sin phosphatase activation [75]. These findings led to
the proposal of a role of ROCK in coronary vasos-
pasm. In idiopathic pulmonary hypertension, ROCK2
is highly expressed in pulmonary arteries of patients
and fasudil treatment induces acute pulmonary vasodi-
lation [76]. Consistently, the selective loss of ROCK2
in vascular smooth muscle prevents development of
chronic hypoxia-induced pulmonary hypertension in
mice, suggesting the causative relation of ROCK2 in
this disease. Other studies using ROCK1 and ROCK2
KO mice and ROCK inhibitors in various animal
models indicate the involvement of ROCK in diabetic
vasculopathy, ischemia/reperfusion injury, heart fail-
ure, cardiac hypertrophy, and fibrosis [77]. Interest-
ingly, in aortic constriction model, the cardiomyocyte-
specific deletion of ROCK2 suppressed the cardiac
hypertrophy [78], while the ROCK1 haploinsufficiency
did not prevent cardiac hypertrophy but reduced fibro-
sis under the same condition [79]. A profibrotic role of
ROCK is also reported in various organs including
lung [80].
Immunity
Early studies on the role of Rho in the immune system
focused on its role in development, activation and
migration of T cells and B cells [81]. For example,
studies on mice expressing C3 or active RhoA in T cell
lineages suggested that Rho is important in thymocyte
expansion but dispensable for T cell development itself
[82,83]. Indeed, deficiency of RhoA in T cells does not
completely suppress but significantly attenuates in T
cell receptor-dependent proliferative response [84].
Inactivation of Rho and treatment with ROCK inhibi-
tors impairs T cell migration. The most notable feature
is deficit in transendothelial migration due to impaired
uropod retraction [85], a feature shared with neural
precursors, macrophages, neutrophils and cancer cells
[66,86–88]. Recent studies have focused more on the
role of ROCK in the differentiation of T helper cell
(Th) subsets and its pathological significance [89].
Rho-ROCK signaling appears to function in both the
sensitization phase and effector phase of Th2-depen-
dent allergic inflammation. T cell-specific deletion of
RhoA impaired Th2 differentiation but not Th1 differ-
entiation in vitro and prevented OVA-induced allergic
inflammation in vivo with reduction in IgE level, cell
infiltration in the airway and Th2 cytokine production
[84]. Administration of fasudil all through the experi-
mental period mimicked these effects of RhoA defi-
ciency. In addition, inhalation of Y-27632 during the
allergen challenge could suppress airway constriction
and hypersensitivity and partially prevented cell infil-
tration to the airway in an OVA-induced asthma
model of guinea pig [90]. These effects of Y-27632
may well be due to the suppression of enhanced cal-
cium sensitization of airway smooth muscle contrac-
tion induced by allergen-sensitization [91], and effects
of ROCK inhibition on chemotaxis of inflammatory
cells. Studies using ROCK hetero-deficient mice indi-
cate that both ROCK1 and ROCK2 in lymphocytes
and nonlymphocyte cells are involved in these pro-
cesses [92,93].
The more intriguing findings on the role of ROCK
in Th subsets are that of ROCK2 in Th17 cells. This
was first reported by the Pernis group, who found
that ROCK2 is selectively activated in CD4+ T cells
under Th17 skewing conditions and phosphorylates
interferon regulatory factor-4 (IRF-4) to facilitate
Th17 cell differentiation and that administration of
ROCK inhibitor suppresses production of Th17
cytokines, IL-21 and IL-17, and ameliorates symp-
toms in autoimmune model mice [94]. Concurrently,
Kadmon Pharmaceuticals ran Phase 1 clinical trial of
a ROCK2-selective inhibitor, KD025 [95,96]. Zanin-
Zhorov et al. [96] analyzed responses of peripheral
blood mononuclear cells (PBMCs) from human sub-
jects in the above trial and found that KD025 admin-
istration in vivo significantly inhibited ex vivo secretion
of IL-21 and IL-17 from activated PBMCs. They con-
firmed this effect in human CD4+ T cells stimulated
in vitro under the Th17 skewing conditions, and found
that it is through suppression of STAT3 phosphoryla-
tion. Intriguingly, while KD025 suppresses Th17
differentiation through decreased STAT3 phosphory-
lation, it accelerates regulatory T cell (Treg) differenti-
ation through enhanced STAT5 phosphorylation. The
effect of KD025 to suppress IL-17 and IL-21 produc-
tion was then confirmed in PBMCs from patients with
rheumatoid arthritis, graft-versus-host disease, sys-
temic lupus erythematosus and inflammatory bowel
diseases [96–99]. Further, recent Phase 2 studies
showed that oral administration of KD025 reduces
clinical scores in psoriasis patients with concomitant
decrease in plasma levels of IL-17 and IL-23 and
increase in that of IL-10 [100].
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Cancer
Since many dbl-containing Rho GEFs were isolated by
transformation assay of cultured fibroblasts [101] and
Rho-GAP domain-containing DLC-1 (Deleted in Liver
Cancer-1) is downregulated in various tumors and is
regarded as a tumor suppressor [102], Rho GTPases
have been implicated in cell transformation and onco-
genesis. Indeed, earlier works showed requirement of
Rho GTPases in Ras-mediated cell-transformation
[103]. Notably, while these studies used GTPase-defi-
cient G14V or Q63L in RhoA and G12V or Q61L
Rac1 analogous to oncogenic Ras mutations, such
mutations in Rho GTPases have not been detected in
clinical cancer. On the contrary, fast cycling P29S,
P29L, and P29Q mutations in Rac1 have been identi-
fied by high-throughput sequencing of clinical human
cancers [104–106], the G17V RhoA mutation frequent
found in T cell lymphomas [107,108] and the Y42C
RhoA mutation recurrently in diffuse gastric cancer
[109]. Since biochemical properties of these RhoA
mutation are not clear, how these RhoA mutations
induces oncogenesis is an interesting question to be
solved [110]. In addition to these mutations in Rho
GTPases, more than 600 somatic coding mutations in
ROCK1 and ROCK2 have been identified in human
cancers and downregulation of miRNAs targeting
ROCK1 and ROCK2, and, consequently upregulation
of ROCKs has been shown in malignant tissues [111].
This enhanced ROCK signaling could facilitate cell
transformation for tumor cell survival and growth. Y-
27632 treatment was reported to inhibit transforma-
tion of NIH3T3 cells by Dbl and Ras [112], and condi-
tional deletion of ROCK1 and ROCK2 in
combination was shown to inhibit transformation of
cells derived from Ras-driven lung tumors and Raf-
driven melanomas [113]. ROCK signaling likely func-
tions in tumor cell invasion and metastasis, which was
first shown in the peritoneal tumor dissemination
model [88]. Tumor cells can migrate as single cells or
collectively as a cluster. Experiments in three-dimen-
sional matrix suggest that tumor cells adopt two differ-
ent modes of single-cell migratory mechanisms, Rac-
mediated elongated mesenchymal migration and
ROCK-mediated rounded amoeboid migration, which
are interconvertible and utilized in the context-depen-
dent manner [114]. ROCK signaling also enables tail
retraction in transendothelial and transepithelial
migration of tumor cells [88]. ROCK can also remodel
extracellular matrix in tumor microenvironment for
tumor invasion. Sanz-Moreno et al. [115] showed in
collagen matrix model that increased ROCK signaling
induced by cytokine contracts stromal fibroblasts to
create tracks for collective migration of squamous car-
cinoma cells. Rath et al. [116] showed that ROCK
activation in mouse pancreatic ductal adenocarcinoma
cells increased their invasive growth into a three-
dimensional collagen matrix by extensive induction of
matrix metalloproteinases and increased matrix remod-
eling. These findings combined together suggest that
Fig. 3. Milestone discoveries in Rho signaling research.
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Rho-ROCK signaling is not the primary cause but
critical for several important phenotypes of cancer,
which may be exploited therapeutically in combination
with other anticancer therapies [111].
Future prospects
Although a substantial amount of work has been done
since the discovery of Rho more than 30 years ago,
elucidating important physiological roles of this
GTPase family and their action mechanisms as
described above (Fig. 3), the whole picture of the biol-
ogy of Rho, how each member of the Rho family
GTPases is activated under what conditions in which
tissue, exerts which body function by acting on which
effectors, is still far from complete. Generation and
analysis of tissue-specific conditional knockout mice
deficient in each member of Rho GTPases, effectors
and regulatory proteins, GEFs and GAPs, could help
our understanding. This is true even for each of classic
Rho member, RhoA, RhoB, and RhoC. Most of the
earlier studies on Rho described above have been car-
ried out on RhoA, and it is not certain whether other
Rho members exert the same actions in the cell.
Although some studies suggest the redundant roles
between these RhoA, RhoB, and RhoC isoforms
[117,118], their different cellular localization and dif-
ferent regulatory modes of expression strongly suggest
that they play also context- and localization-dependent
distinct roles in the cell and possibly in the body [119].
For example, although these three Rho members simi-
larly interact with Rho effectors thus far identified,
RhoA, RhoB, and RhoC act on different effectors,
namely ROCKi/2, integrins and formin FMNL3,
respectively, and exert different functions in cancer cell
migration and morphogenesis [120]. RhoB shows
unique endosome localization, and is suggested to
exert different functions from RhoA and RhoC [121].
Furthermore, while RhoA-null mice are embryonic
lethal [122], RhoB-null and RhoC-null mice are viable
[123,124]. There are also issues on atypical Rho
GTPases such as Rnd proteins, RhoBTB proteins,
RhoH, RhoU and RhoV [119]. More remains to be
clarified on their regulatory and effector mechanisms,
and again their body function. As for Rho GTPase
activation, there are 70 Rho GEFs of Dbl homology
and 10 DOCK homologs. Studies have been in pro-
gress elucidating what physiological context each GEF
is activated and contributes to, one classic examples
being p115 RhoA-GEF coupling to Ga12/13 for cell
contraction [125]. Given such importance of Rho and
Rho regulators and effectors in many biological pro-
cesses, the studies on the dynamics of their activation
and termination, that is how Rho and Rho regulators
and effectors are activated at the right time and place,
and how this signal propagates in the living cell in a
variety of physiological processes, is an important
issue. The challenge is nanoscale imaging of spatiotem-
poral actions of Rho-Rho effectors not only in living
cultured cells but also hopefully in intact tissues or
intact body. Such studies combined with the systematic
analysis on the functions of Rho signaling at respective
sites will help to elucidate the pictures of Rho actions
in the body. Finally, our understanding on the roles of
Rho and Rho effectors in pathophysiology has just
begun. As illustrated by the recent discovery of the
role of ROCK2 in autoimmunity and the therapeutic
effects of its selective inhibitor [100], unraveling the
roles of Rho and Rho effectors further in various
pathophysiological settings by the above approach
may reveal unappreciated therapeutic possibilities.
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